{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fquadshot-news-podcast.simplecast.com%2Fepisodes%2F482024-keynote-412-C_V_Y1sf","width":444,"version":"1.0","type":"rich","title":"4.8.2024 - KEYNOTE 412","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/d4956b26-f7a3-4f47-a83d-9293649d65c8/ec08e780-4e06-4c01-8109-4e894d682296/qs_sqaure.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/8d05107c-b0fb-445a-a41d-d5b44eaf9c91\" height=\"200\" width=\"100%\" title=\"4.8.2024 - KEYNOTE 412\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Check out this week's QuadCast as we highlight pembro + CRT for head and neck cancer, the benefit of treating the primary tumor in NSCLC with brain mets, the potential protection of estrogen against head and neck cancer, and more."}